Stryker’s neurovascular president Jim Marucci on Cerus acquisition, Target Tetra and AI/AR potential

In this episode of StrykerTalks, neurovascular president Jim Marucci discusses the company’s latest advancements in neurovascular technology and how that, and its expanding global footprint, are shaping the future of its neurovascular division.

Marucci details the company’s recent strategic acquisition of Cerus Endovascular, which has increased Stryker’s capabilities in treating wide-neck bifurcated aneurysms. Furthering Stryker’s goal to simplify procedures, reduce costs, and improve patient outcomes.

The conversation also touches on developing new products like the Target Tetra detachable coil for smaller aneurysms and the potential of emerging technologies like AI, AR, and VR in neurovascular procedures. Marucci anticipates these technologies will play a crucial role in advancing the field and improving access to care globally.

Tune in for a comprehensive overview of Stryker’s current strategies, product innovations, and future directions in the neurovascular sector, underlining its commitment to enhancing stroke care and neurovascular treatments worldwide.

Thank you to Zeus for sponsoring this episode. To learn more about how Zeus works with medical device companies, visit www.zeusinc.com. 

Thank you for listening to the StrykerTalks Podcast.

Subscribe to this podcast on every major podcast platform.